This page has only limited features, please log in for full access.

Dr. J. Gratacós
Rheumatology and immuno-mediated diseases

Basic Info


Research Keywords & Expertise

0 Psoriatic Arthritis
0 Spondyloarthritis
0 covid-19
0 SARS-CoV-2
0 lymphocyte subsets

Fingerprints

Psoriatic Arthritis
Spondyloarthritis
covid-19
SARS-CoV-2
lymphocyte subsets

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Preprint content
Published: 19 July 2021
Reads 0
Downloads 0

Background: To evaluate the influence of the disease activity on radiographic progression in axial spondyloarthritis (axSpA) patients treated with TNF inhibitors (TNFi).Methods: The study included 101 axSpA patients from the Spanish Register of Biological Therapy in Spondyloarthritides (REGISPONSERBIO), which had clinical data and radiographic assessment available. Patients were classified into 2 groups based on the duration of TNFi treatment at baseline: i) long-term treatment (≥4 years) and ii) no long-term treatment (< 4 years). Radiographs were scored by two readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) with known chronology. Disease activity differences between patients’ groups at each time point were assessed using a linear mixed-effect model.Results: Radiographic progression was defined as an increase in ≥2 mSASSS units. At inclusion, approximately half of the patients (45.5%) were receiving long-term treatment with TNFi (≥4 years). In this group of subjects, a significant difference in averaged Ankylosing Spondylitis disease Activity Score (ASDAS) across follow-up was found between progressors and non-progressors (2.33 vs 1.76, p=0.027, respectively). In patients not under long-term TNFi treatment (54.5%) though, no significant ASDAS differences were observed between progressors and non-progressors until the third year of follow-up. Furthermore, no significant differences were found in progression status, when disease activity was measured by Bath Ankylosing spondylitis Disease Activity Index (BASDAI) and C reactive protein (CRP).Conclusions: Patients on long-term TNFi treatment with a mean sustained low disease activity measures by ASDAS presented lower radiographic progression than those with active disease.

ACS Style

Maria Llop; Mireia Moreno; Victoria Navarro-Compán; Xavier Juanola; Eugenio de Miguel; Raquel Almodóvar; Eduardo Cuende Quintana; Jesús Sanz Sanz; Emma Beltrán; Maria Dolores Ruiz Montesinos; Joan Calvet; Antoni Berenguer-Llergo; Jordi Gratacós Masmitjà. Sustained Low Disease Activity Measured By ASDAS Slow Radiographic Spinal Progression in Axial Spondyloarthritis Patients Treated With TNF-inhibitors. Data from REGISPONSERBIO. 2021, 1 .

AMA Style

Maria Llop, Mireia Moreno, Victoria Navarro-Compán, Xavier Juanola, Eugenio de Miguel, Raquel Almodóvar, Eduardo Cuende Quintana, Jesús Sanz Sanz, Emma Beltrán, Maria Dolores Ruiz Montesinos, Joan Calvet, Antoni Berenguer-Llergo, Jordi Gratacós Masmitjà. Sustained Low Disease Activity Measured By ASDAS Slow Radiographic Spinal Progression in Axial Spondyloarthritis Patients Treated With TNF-inhibitors. Data from REGISPONSERBIO. . 2021; ():1.

Chicago/Turabian Style

Maria Llop; Mireia Moreno; Victoria Navarro-Compán; Xavier Juanola; Eugenio de Miguel; Raquel Almodóvar; Eduardo Cuende Quintana; Jesús Sanz Sanz; Emma Beltrán; Maria Dolores Ruiz Montesinos; Joan Calvet; Antoni Berenguer-Llergo; Jordi Gratacós Masmitjà. 2021. "Sustained Low Disease Activity Measured By ASDAS Slow Radiographic Spinal Progression in Axial Spondyloarthritis Patients Treated With TNF-inhibitors. Data from REGISPONSERBIO." , no. : 1.

Research article
Published: 15 March 2021 in PLOS ONE
Reads 0
Downloads 0

Objective To analyze the performance of psoriatic arthritis (PsA) screening tools, examine their implementation in daily practice, and reach a consensus about the best screening tool for implementation in daily practice in different medical settings. Methods A systematic literature review (SLR), structured telephone interviews to hospitals, and a multidisciplinary nominal group meeting were all conducted. The SLR employed sensitive search strategies using Medline, Embase, and the Cochrane Library up to January 2020. Two reviewers independently selected articles that reported data on PsA screening tools and that included sufficient data to at least calculate the sensitivity and specificity of those tools (e.g., questionnaires, algorithms, specific questions, and biomarkers). The hospital interviews collected data regarding the process of suspected PsA diagnosis and referral to rheumatology, the implementation of PsA screening tools, and barriers and facilitators to implementation of those tools. In the nominal group meeting, a multidisciplinary team of experts discussed all these data and subsequently recommended a screening tool for implementation. Results The SLR included 41 moderate-quality studies that analyzed 14 PsA screening tools, most of which were questionnaire-based tools. All of these studies reported a moderate-good performance but presented different characteristics regarding the time to completion or the number and type of items or questions. The implementation of screening tools was low (30.5%). The experts ultimately recommended regular use of a PsA screening tool, preferably the PURE-4 questionnaire. Conclusions The implementation of PsA screening tools like the PURE-4 questionnaire in daily practice likely improves the prognosis of PsA patients.

ACS Style

Ana Urruticoechea-Arana; Diego Benavent; Fernando León; Raquel Almodovar; Isabel Belinchón; Pablo de la Cueva; Cristina Fernández-Carballido; Estíbaliz Loza; Jordi Gratacós; Cribado Working Group. Psoriatic arthritis screening: A systematic literature review and experts’ recommendations. PLOS ONE 2021, 16, e0248571 .

AMA Style

Ana Urruticoechea-Arana, Diego Benavent, Fernando León, Raquel Almodovar, Isabel Belinchón, Pablo de la Cueva, Cristina Fernández-Carballido, Estíbaliz Loza, Jordi Gratacós, Cribado Working Group. Psoriatic arthritis screening: A systematic literature review and experts’ recommendations. PLOS ONE. 2021; 16 (3):e0248571.

Chicago/Turabian Style

Ana Urruticoechea-Arana; Diego Benavent; Fernando León; Raquel Almodovar; Isabel Belinchón; Pablo de la Cueva; Cristina Fernández-Carballido; Estíbaliz Loza; Jordi Gratacós; Cribado Working Group. 2021. "Psoriatic arthritis screening: A systematic literature review and experts’ recommendations." PLOS ONE 16, no. 3: e0248571.

Journal article
Published: 15 January 2021 in Revue du Rhumatisme
Reads 0
Downloads 0

Objectif: analyser l’association potentielle entre la présence de HLA-B27 et les différentes comorbidités observées chez les patients atteints de spondyloarthrite axiale. Méthodes: une étude comparative transversale incluant des patients ayant une spondyloarthrite axiale et issus du registre COMOSPA ; COMOSPA est un registre international qui regroupe un grand nombre de variables anthropométriques et cliniques provenant de 3984 patients atteints de spondyloarthrite. Le registre comprend également les comorbidités les plus fréquemment observées au cours de la spondyloarthrite comme l’obésité, l’hypertention, le diabète, l’hyperlipidémie, la cardiopathie ischémique, l’AVC, l’insuffisance rénale, les néoplasmes, l’ulcère gastro-duodénal, la diverticulite, la bronchopneumopathie chronique obstructive et l’ostéoporose. Une analyse descriptive et un modèle de régression logistique multiple ont été réalisés en incluant toutes les variables évaluées. Résultats: 2370 patients répondant aux critères ASAS pour la spondyloarthrite axiale ont été inclus dans cette étude. Parmi eux, 1858 (78,4 %) étaient positifs pour le HLA-B27. Les patients souffrant de spondyloarthrite axiale et HLA-B27 positifs étaient majoritairement de sexe masculin, avec une maladie de plus longue durée, un pourcentage supérieur de spondylarthrites ankylosantes avérées, une CRP plus élevée mais également un tabagisme et une consommation excessive d’alcool plus marqués comparativement aux patients HLA-B27 négatifs. À noter cependant qu’une forme plus active de la maladie selon le BASDAI, BASFI et l’ADAS-CRP a été rapportée chez les patients négatifs pour le HLA-B27 comparativement aux patients positifs. La seule association observée entre les comorbidités et la positivité pour le HLA-B27 a été la présence de l’ostéoporose, même après ajustement dans l’analyse multivariée sur toutes les variables étudiées. Conclusion: l’association observée entre le HLA-B27 et l’ostéoporose dans la spondyloarthrite axiale pourrait avoir un intérêt tout particulier si l’on considère l’impact de l’ostéoporose sur le phénotype de ces patients.

ACS Style

Marta Arévalo; Clementina López-Medina; Mireia Moreno; Anna Moltó; Pilar Font; Eduardo Collantes-Estevez; Jordi Gratacós. Rôle de l’antigène HLA-B27 dans les comorbidités observées au cours de la spondyloarthrite axiale : données du registre COMOSPA. Revue du Rhumatisme 2021, 88, 130 -133.

AMA Style

Marta Arévalo, Clementina López-Medina, Mireia Moreno, Anna Moltó, Pilar Font, Eduardo Collantes-Estevez, Jordi Gratacós. Rôle de l’antigène HLA-B27 dans les comorbidités observées au cours de la spondyloarthrite axiale : données du registre COMOSPA. Revue du Rhumatisme. 2021; 88 (2):130-133.

Chicago/Turabian Style

Marta Arévalo; Clementina López-Medina; Mireia Moreno; Anna Moltó; Pilar Font; Eduardo Collantes-Estevez; Jordi Gratacós. 2021. "Rôle de l’antigène HLA-B27 dans les comorbidités observées au cours de la spondyloarthrite axiale : données du registre COMOSPA." Revue du Rhumatisme 88, no. 2: 130-133.

Review
Published: 17 December 2020 in Advances in Therapy
Reads 0
Downloads 0

Therapeutic approaches for psoriatic arthritis (PsA) include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors. This systematic review aimed to provide complete and up-to-date information on efficacy of tofacitinib in the treatment of PsA, giving special attention to non-skin manifestations (peripheral arthritis, axial disease, enthesitis, and dactylitis). A search of studies published between January 2016 and June 2020 was carried out on PubMed and Google Scholar. The number of studies with tofacitinib in PsA is limited and most of them are post hoc analyses from OPAL Broaden and OPAL Beyond. Tofacitinib has been demonstrated to be efficacious for the treatment of all disease manifestations in PsA. Superior effectivity to placebo is achieved at the earliest time point evaluated, and maintained over time. Patients who switch from placebo to tofacitinib show the same improvements; however, the time to initial response is faster in patients who firstly receive tofacitinib, compared with those switching subsequently. Additional data suggest that tofacitinib may be also effective for the treatment of the axial domain. Tofacitinib has been demonstrated to be efficacious for the treatment of peripheral and axial involvement, enthesitis, and dactylitis manifestation in PsA. Further prospective and long-term studies are required to corroborate and complete the present results. Similarly, real-world evidence is also necessary to complement the information obtained in clinical trials, and thereby to have a better overview of real efficacy and safety of the drug.

ACS Style

Jordi Gratacós Masmitjà; Carlos M. González Fernández; Susana Gómez Castro; Francisco José Rebollo Laserna. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Advances in Therapy 2020, 38, 868 -884.

AMA Style

Jordi Gratacós Masmitjà, Carlos M. González Fernández, Susana Gómez Castro, Francisco José Rebollo Laserna. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Advances in Therapy. 2020; 38 (2):868-884.

Chicago/Turabian Style

Jordi Gratacós Masmitjà; Carlos M. González Fernández; Susana Gómez Castro; Francisco José Rebollo Laserna. 2020. "Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review." Advances in Therapy 38, no. 2: 868-884.

Journal article
Published: 03 December 2020 in Reumatología Clínica
Reads 0
Downloads 0

Although non-radiographic axial spondyloarthritis (EspAax-nr) is well understood within health institutions, being considered along with radiographic EspAax (EspAax-r) as part of the same disease spectrum, patient understanding is unknown. The aim is to describe the patient's knowledge of the EspAax-nr entity. Atlas 2017, promoted by the Spanish Federation of Spondylarthritis Associations (CEADE), aims to comprehensively understand the reality of EspAax patients from a holistic approach. A cross-sectional on-line survey of unselected patients with self-reported EspAax diagnosis from Spain was conducted. Participants were asked to report their diagnosis. Socio-demographic, disease characteristics and patient-reported outcomes (PROs) were compared between those patients self-reporting as EspAax-nr and EspAax-r. 634 EspAax patients participated. Mean age 45.7 ± 10.9 years, 50.9% female and 36.1% university-educated. 35 (5.2%) self-reported as EspAax-nr. Compared to EspAax-r patients, those with EspAax-nr were more frequently women (48.6% vs 91.4%, p < 0.001), had longer diagnostic delay (10.1 ± 8.9 vs 8.5 ± 7.6 years), higher psychological distress (GHQ-12: 7.5 ± 4.9 vs 5.6 ± 4.4) and similar degree of disease activity (BASDAI: 5.7 ± 2.1 vs 5.7 ± 2.0), and unemployment rates (20.0% vs 21.6%). 20.0% of EspAax-nr received biologics vs 36.9% of EspAax-r, p = 0.043. Visits to the rheumatologist in the past year were similar in both groups (3.8 ± 4.5 vs 3.2 ± 3.8), while GP visits were much higher within EspAax-nr (8.0 ± 10.7 vs 4.9 ± 13.3 p = 0.003). For the first time, EspAax-nr characteristics and PROs have been analyzed from the patient's perspective. Both groups reported similar trends with the exception of EspAax-nr being more frequently women, younger, having longer diagnostic delay and lower use of biologic therapy. Aunque se comprende bien la espondiloartritis axial no radiográfica (EspAax-nr) dentro de las instituciones sanitarias, se desconoce la comprensión del paciente cuando se considera conjuntamente con la espondiloartritis axial radiográfica (r-axSpA), como parte del mismo espectro de la enfermedad. El objetivo de este artículo es describir el conocimiento del paciente de la entidad EspAax-nr. El objetivo de Atlas 2017, promovido por la Federación Española de Asociaciones de Espondiloartritis (CEADE), es comprender la realidad de los pacientes con espondiloartritis axial (EspAax) desde un enfoque holístico. Se realizó una encuesta transversal online a pacientes españoles no seleccionados, con diagnóstico autoreportado de axSpA. Se solicitó a los participantes que informaran su diagnóstico. Se compararon las características sociodemográficas y los resultados reportados por el paciente (RPO) entre los pacientes que autoreportaron EspAax-nr y EspAax-r. Participaron 634 pacientes de EspAax, con edad media de 45,7 ± 10,9 años, siendo mujeres el 50,9%, y un 36,1% con formación universitaria. Treinta y cinco de ellas (5,2%) autoreportaron EspAax-nr. En comparación con los pacientes de EspAax-r, aquellos con EspAax-nr eran mujeres con mayor frecuencia (48,6 vs. 91,4%, p < 0,001), tenían mayor demora en el diagnóstico (10,1 ± 8,9 vs. 8,5 ± 7,6 años), y mayor grado de angustia psicológica (12-item general health questionnaire [GHQ-12]: 7,5 ± 4,9 vs. 5,6 ± 4,4) y grado similar de actividad de la enfermedad (bath ankylosing spondylitis disease activity index [BASDAI]: 5,7 ± 2,1 vs. 5,7 ± 2), y tasas de desempleo (20 vs. 21,6%). El 20% de los pacientes de EspAax-nr recibían terapia biológica vs. el 36,9% de pacientes de r-axSpA, p = 0,043. Las visitas al reumatólogo el año anterior fueron similares en ambos grupos (3,8 ± 4,5 vs. 3,2 ± 3,8), mientras que las visitas al médico de atención primaria eran más frecuentes dentro del grupo de nr-axSpA (8 ± 10,7 vs. 4,9 ± 13,3 p = 0,003). Por vez primera, se han analizado las características de EspAax-nr y PRO desde la perspectiva del paciente. Ambos grupos reportaron tendencias similares, exceptuando que el grupo de EspAax-nr estaba más frecuentemente formado por mujeres, más jóvenes, con mayor demora en el diagnóstico y menor uso de terapia biológica.

ACS Style

Marco Garrido-Cumbrera; Jordi Gratacos; Eduardo Collantes-Estevez; Pedro Zarco; Carlos Sastre; Sergio Sanz-Gómez; Victoria Navarro-Compán. Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas. Reumatología Clínica 2020, 1 .

AMA Style

Marco Garrido-Cumbrera, Jordi Gratacos, Eduardo Collantes-Estevez, Pedro Zarco, Carlos Sastre, Sergio Sanz-Gómez, Victoria Navarro-Compán. Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas. Reumatología Clínica. 2020; ():1.

Chicago/Turabian Style

Marco Garrido-Cumbrera; Jordi Gratacos; Eduardo Collantes-Estevez; Pedro Zarco; Carlos Sastre; Sergio Sanz-Gómez; Victoria Navarro-Compán. 2020. "Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas." Reumatología Clínica , no. : 1.

Journal article
Published: 09 November 2020 in Viruses
Reads 0
Downloads 0

Background: COVID-19 pathophysiology and the predictive factors involved are not fully understood, but lymphocytes dysregulation appears to play a role. This paper aims to evaluate lymphocyte subsets in the pathophysiology of COVID-19 and as predictive factors for severe disease. Patient and methods: A prospective cohort study of patients with SARS-CoV-2 bilateral pneumonia recruited at hospital admission. Demographics, medical history, and data regarding SARS-CoV-2 infection were recorded. Patients systematically underwent complete laboratory tests, including parameters related to COVID-19 as well as lymphocyte subsets study at the time of admission. Severe disease criteria were established at admission, and patients were classified on remote follow-up according to disease evolution. Linear regression models were used to assess associations with disease evolution, and Receiver Operating Characteristic (ROC) and the corresponding Area Under the Curve (AUC) were used to evaluate predictive values. Results: Patients with critical COVID-19 showed a decrease in CD3+CD4+ T cells count compared to non-critical (278 (485 IQR) vs. 545 (322 IQR)), a decrease in median CD4+/CD8+ ratio (1.7, (1.7 IQR) vs. 3.1 (2.4 IQR)), and a decrease in median CD4+MFI (21,820 (4491 IQR) vs. 26,259 (3256 IQR)), which persisted after adjustment. CD3+CD8+ T cells count had a high correlation with time to hospital discharge (PC = −0.700 (−0.931, −0.066)). ROC curves for predictive value showed lymphocyte subsets achieving the best performances, specifically CD3+CD4+ T cells (AUC = 0.756), CD4+/CD8+ ratio (AUC = 0.767), and CD4+MFI (AUC = 0.848). Conclusions: A predictive value and treatment considerations for lymphocyte subsets are suggested, especially for CD3CD4+ T cells. Lymphocyte subsets determination at hospital admission is recommended.

ACS Style

Joan Calvet; Jordi Gratacós; María Amengual; Maria Llop; Marta Navarro; Amàlia Moreno; Antoni Berenguer-Llergo; Alejandra Serrano; Cristóbal Orellana; Manel Cervantes. CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. Viruses 2020, 12, 1277 .

AMA Style

Joan Calvet, Jordi Gratacós, María Amengual, Maria Llop, Marta Navarro, Amàlia Moreno, Antoni Berenguer-Llergo, Alejandra Serrano, Cristóbal Orellana, Manel Cervantes. CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. Viruses. 2020; 12 (11):1277.

Chicago/Turabian Style

Joan Calvet; Jordi Gratacós; María Amengual; Maria Llop; Marta Navarro; Amàlia Moreno; Antoni Berenguer-Llergo; Alejandra Serrano; Cristóbal Orellana; Manel Cervantes. 2020. "CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study." Viruses 12, no. 11: 1277.

Correction
Published: 11 June 2020 in Arthritis Research & Therapy
Reads 0
Downloads 0

An amendment to this paper has been published and can be accessed via the original article.

ACS Style

Marta Arévalo; Jordi Gratacós Masmitjà; Mireia Moreno; Joan Calvet; Cristobal Orellana; Desirée Ruiz; Carmen Castro; Pilar Carreto; Marta Larrosa; Eduardo Collantes; Pilar Font; Eduardo Collantes Estévez; Xavier Juanola Roura; Jose Luis Fernández Sueiro; Carlos González Fernández; Juan Mulero Mendoza; Juan Carlos Torre Alonso; Pilar Fernández Dapica; Enrique Batlle Gualda; Luis F. Linares Ferrando; Enrique Judez Navarro; Carlos Vázquez Galeano; Teresa Clavaguera Poch; Mª. Cruz Fernández Espartero; Enrique Calero Secall; Manuel Pujol Busquets; Carlos Rodríguez Lozano; Manuel J. Moreno Ramos; Eduardo Cuende Quintana; Manuel Fernández Prada; Rubén Queiro Silva; Estefanía Moreno Ruzafa; Carlos Montilla Morales; Alicia García López; Eugenio Giménez Úbeda; Antonio Juan Más; Cristina Medrano Le Quement; Enrique Ornilla; REGISPONSER group. Correction to: Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Research & Therapy 2020, 22, 1 -1.

AMA Style

Marta Arévalo, Jordi Gratacós Masmitjà, Mireia Moreno, Joan Calvet, Cristobal Orellana, Desirée Ruiz, Carmen Castro, Pilar Carreto, Marta Larrosa, Eduardo Collantes, Pilar Font, Eduardo Collantes Estévez, Xavier Juanola Roura, Jose Luis Fernández Sueiro, Carlos González Fernández, Juan Mulero Mendoza, Juan Carlos Torre Alonso, Pilar Fernández Dapica, Enrique Batlle Gualda, Luis F. Linares Ferrando, Enrique Judez Navarro, Carlos Vázquez Galeano, Teresa Clavaguera Poch, Mª. Cruz Fernández Espartero, Enrique Calero Secall, Manuel Pujol Busquets, Carlos Rodríguez Lozano, Manuel J. Moreno Ramos, Eduardo Cuende Quintana, Manuel Fernández Prada, Rubén Queiro Silva, Estefanía Moreno Ruzafa, Carlos Montilla Morales, Alicia García López, Eugenio Giménez Úbeda, Antonio Juan Más, Cristina Medrano Le Quement, Enrique Ornilla, REGISPONSER group. Correction to: Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Research & Therapy. 2020; 22 (1):1-1.

Chicago/Turabian Style

Marta Arévalo; Jordi Gratacós Masmitjà; Mireia Moreno; Joan Calvet; Cristobal Orellana; Desirée Ruiz; Carmen Castro; Pilar Carreto; Marta Larrosa; Eduardo Collantes; Pilar Font; Eduardo Collantes Estévez; Xavier Juanola Roura; Jose Luis Fernández Sueiro; Carlos González Fernández; Juan Mulero Mendoza; Juan Carlos Torre Alonso; Pilar Fernández Dapica; Enrique Batlle Gualda; Luis F. Linares Ferrando; Enrique Judez Navarro; Carlos Vázquez Galeano; Teresa Clavaguera Poch; Mª. Cruz Fernández Espartero; Enrique Calero Secall; Manuel Pujol Busquets; Carlos Rodríguez Lozano; Manuel J. Moreno Ramos; Eduardo Cuende Quintana; Manuel Fernández Prada; Rubén Queiro Silva; Estefanía Moreno Ruzafa; Carlos Montilla Morales; Alicia García López; Eugenio Giménez Úbeda; Antonio Juan Más; Cristina Medrano Le Quement; Enrique Ornilla; REGISPONSER group. 2020. "Correction to: Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database." Arthritis Research & Therapy 22, no. 1: 1-1.

Review
Published: 14 May 2020 in Current Rheumatology Reports
Reads 0
Downloads 0

International guidelines for axial spondyloarthritis (axSpA) suggest that patients benefit from becoming members of patient associations. However, the scientific evidence for this is limited and unconvincing. The objective of this study was to evaluate the differences in sociodemographic characteristics, lifestyle habits, and patient-reported outcomes (PROs) between axSpA patients belonging to patient associations versus those who do not. Out of 680 patients, 301 (44.3%) were members of a patient association. A significant proportion of association members were found to engage in physical activities considered appropriate to their condition (48.2% vs. 39.8%, p = 0.03), and smoked significantly less compared with their non-association counterparts (22.7% vs. 33.6%, p = 0.02). In addition, despite having longer disease duration, and receiving similar treatments, members of associations reported significantly lower disease activity (BASDAI 5.1 vs. 5.8; p < 0.001), less functional limitations (Functional Limitation Index 26.4 vs. 28.6; p < 0.05), and a lower risk of psychological distress (GHQ-12 4.9 vs. 6.5; p < 0.001). The results of this study suggest there are beneficial effects of belonging to a patient association for managing axSpA, since those member patients experience better lifestyle habits and PROs than those who do not so participate. Rheumatologists should encourage patients to enroll in patient associations for a holistic approach to managing their condition.

ACS Style

Marco Garrido-Cumbrera; on behalf of the Atlas working group; Jorge Chacón-García; Victoria Navarro-Compán; Jordi Gratacós; Sergio Sanz-Gómez; Eduardo Collantes-Estevez. Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. Current Rheumatology Reports 2020, 22, 1 -8.

AMA Style

Marco Garrido-Cumbrera, on behalf of the Atlas working group, Jorge Chacón-García, Victoria Navarro-Compán, Jordi Gratacós, Sergio Sanz-Gómez, Eduardo Collantes-Estevez. Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. Current Rheumatology Reports. 2020; 22 (6):1-8.

Chicago/Turabian Style

Marco Garrido-Cumbrera; on behalf of the Atlas working group; Jorge Chacón-García; Victoria Navarro-Compán; Jordi Gratacós; Sergio Sanz-Gómez; Eduardo Collantes-Estevez. 2020. "Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey." Current Rheumatology Reports 22, no. 6: 1-8.

Journal article
Published: 03 April 2020 in Joint Bone Spine
Reads 0
Downloads 0

Objective: To analyze the potential association between the presence of HLA-B27 and the different comorbidities observed in Axial Spondyloarthritis patients. Methods: A comparative cross-sectional study including Axial Spondyloarthritis patients from COMOSPA registry. COMOSPA is a worldwide registry that includes a wide set of anthropometric and clinical variables from 3984 patients with Spondyloarthritis. The registry also includes the most frequent comorbidities observed in Spondyloarthitis such as obesity, hypertension, diabetes, hyperlipidemia, heart ischemic disease, stroke, renal failure, neoplasms, peptic ulcer, diverticulitis, chronic obstructive pulmonary disease, and the presence of osteoporosis. A descriptive analysis and a multiple logistic regression model was performed including all variables assessed. Results: 2370 patients fulfilled ASAS criteria of Axial Spondyloarthritis patients and were included in the study. 1858 (78.4%) of them were HLA-B27 positive. HLA-B27 positive Axial Spondyloarthritis patients presented significantly higher percentage of male sex, longer disease duration, higher percentage of definite Ankylosing Spondylitis, higher CRP levels, and were also more frequent tobacco consumers and excessive alcohol intakers compared to the negatives. However, disease activity measured by BASDAI, BASFI and ASDAS-CRP were all significantly higher in the HLA-B27 negative patients compared to the positive ones. The only association observed between any comorbidity and presence of gen HLA-B27 was the presence of osteoporosis, even after adjusting in the multivariate analysis for all variables assessed. Conclusion: The association observed between the gen HLA-B27 and the presence of osteoporosis in Axial Spondyloarthritis patients could be of great relevance given the impact of osteoporosis in the phenotypical frame of these patients.

ACS Style

Marta Arévalo; Clementina López-Medina; Mireia Moreno Martinez-Losa; Anna Moltó; Pilar Font; Eduardo Collantes-Estevez; Jordi Gratacós. Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA. Joint Bone Spine 2020, 87, 445 -448.

AMA Style

Marta Arévalo, Clementina López-Medina, Mireia Moreno Martinez-Losa, Anna Moltó, Pilar Font, Eduardo Collantes-Estevez, Jordi Gratacós. Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA. Joint Bone Spine. 2020; 87 (5):445-448.

Chicago/Turabian Style

Marta Arévalo; Clementina López-Medina; Mireia Moreno Martinez-Losa; Anna Moltó; Pilar Font; Eduardo Collantes-Estevez; Jordi Gratacós. 2020. "Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA." Joint Bone Spine 87, no. 5: 445-448.

Withdrawal
Published: 05 April 2019 in Arthritis Research & Therapy
Reads 0
Downloads 0

Recent data suggest that anti-TNF doses can be reduced in ankylosing spondylitis (AS) patients. Some authors even propose withdrawing treatment in patients in clinical remission; however, at present there is no evidence to support this. To assess how long AS patients with persistent clinical remission remained free of flares after anti-TNF withdrawal and to evaluate the effects of treatment reintroduction. We also analyze the characteristics of patients who did not present clinical relapse. Multicenter, prospective, observational study of a cohort of patients with active AS who had received infliximab as a first anti-TNF treatment and who presented persistent remission (more than 6 months). We recorded at baseline and every 6–8 weeks over the 12-month period the age, gender, disease duration, peripheral arthritis or enthesitis, HLA-B27 status, BASDAI, CRP, ESR, BASFI, and three visual analogue scales, spine global pain, spinal night time pain, and patient’s global assessment. Thirty-six out of 107 patients (34%) presented persistent remission and were included in our study. After treatment withdrawal, 21 of these 36 patients (58%) presented clinical relapse during follow-up. Infliximab therapy was reintroduced and only 52% achieved clinical remission, as they had before the discontinuation of infliximab; in an additional 10%, reintroduction of infliximab was ineffective, obliging us to change the anti-TNF therapy. No clinical or biological factors were associated with the occurrence of relapse during the follow-up. Two thirds of patients in clinical remission presented clinical relapse shortly after infliximab withdrawal. Although the reintroduction of infliximab treatment was safe, half of the patients did not present the same clinical response that they had achieved prior to treatment withdrawal.

ACS Style

Mireia Moreno; REMINEA study Group; Jordi Gratacós; Vicenç Torrente-Segarra; Raimon Sanmarti; Rosa Morlà; Caridad Pontes; Maria Llop; Xavier Juanola. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Research & Therapy 2019, 21, 1 -6.

AMA Style

Mireia Moreno, REMINEA study Group, Jordi Gratacós, Vicenç Torrente-Segarra, Raimon Sanmarti, Rosa Morlà, Caridad Pontes, Maria Llop, Xavier Juanola. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Research & Therapy. 2019; 21 (1):1-6.

Chicago/Turabian Style

Mireia Moreno; REMINEA study Group; Jordi Gratacós; Vicenç Torrente-Segarra; Raimon Sanmarti; Rosa Morlà; Caridad Pontes; Maria Llop; Xavier Juanola. 2019. "Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study." Arthritis Research & Therapy 21, no. 1: 1-6.

Practice guideline
Published: 01 November 2018 in Reumatología Clínica
Reads 0
Downloads 0

Recent data published on biological therapy in axial spondyloarthritis (axSpA) since the last publication of the recommendations of the Spanish Society of Rheumatology (SER) has led to the generation of a review of these recommendations based on the best possible evidence. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with axSpA.Recommendations were drawn up following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Centre for Evidence Based Medicine at Oxford. The level of agreement was established through the Delphi technique.In this review, we did an update of the evaluation of disease activity and treatment objectives. We included the new drugs with approved therapeutic indication for axSpA. We reviewed both the predictive factors of the therapeutic response and progression of radiographic damage. Finally, we drafted some recommendations for the treatment of patients refractory to anti-tumor necrosis factor, as well as for the possible optimization of biological therapy. The document also includes a table of recommendations and a treatment algorithm.We present an update of the SER recommendations for the use of biological therapy in patients with axSpA.

ACS Style

Jordi Gratacós; Petra Díaz Del Campo Fontecha; Cristina Fernández-Carballido; Xavier Juanola Roura; Luis Francisco Linares Ferrando; Eugenio De Miguel Mendieta; Santiago Muñoz Fernández; Jose Luis Rosales-Alexander; Pedro Zarco Montejo; Mercedes Guerra Rodríguez; Victoria Navarro Compán. Recomendaciones de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial. Reumatología Clínica 2018, 14, 320 -333.

AMA Style

Jordi Gratacós, Petra Díaz Del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio De Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez, Victoria Navarro Compán. Recomendaciones de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial. Reumatología Clínica. 2018; 14 (6):320-333.

Chicago/Turabian Style

Jordi Gratacós; Petra Díaz Del Campo Fontecha; Cristina Fernández-Carballido; Xavier Juanola Roura; Luis Francisco Linares Ferrando; Eugenio De Miguel Mendieta; Santiago Muñoz Fernández; Jose Luis Rosales-Alexander; Pedro Zarco Montejo; Mercedes Guerra Rodríguez; Victoria Navarro Compán. 2018. "Recomendaciones de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en espondiloartritis axial." Reumatología Clínica 14, no. 6: 320-333.

Observational study
Published: 03 October 2018 in Arthritis Research & Therapy
Reads 0
Downloads 0

To assess HLA-B27 influence on the clinical phenotype of Ankylosing Spondylitis (AS) patients. An observational, cross-sectional and descriptive study of AS patients from the Spanish REGISPONSER database was performed. Demographic, clinical, disease activity (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP)), and radiographic data (Bath Ankylosing Spondylitis Radiology Index (BASRI) score) were compared regarding HLA-B27 status. A univariate and multivariate analysis was performed to identify variables independently related to the presence of HLA-B27. Data from 1235 patients (74.8% male) were analyzed; 1029 were HLA-B27 positive (83%). HLA-B27-positive patients showed higher family aggregation and an earlier onset of disease compared with those who were HLA-B27 negative. HLA-B27-negative patients presented statistically higher BASDAI and BASFI scores and higher prevalence of arthritis, dactylitis, and extra-articular manifestations (psoriasis and inflammatory bowel disease (IBD)) but not anytime uveitis compared with those who were HLA-B27 positive. In the multivariate analysis, family history (odds ratio (OR) 2.10, 95% confidence interval (CI) 1.27–3.49), younger age at diagnosis (OR 0.97, 95% CI 0.96–0.98), presence of peripheral arthritis (OR 0.53, 95% CI 0.32–0.89), dactylitis (OR 0.16, 95% CI 0.05–0.56), psoriasis (OR 0.45, 95% CI 0.26–0.78), and IBD (OR 0.22, 95% CI 0.12–0.40) were the main variables independently related to the presence or not of HLA-B27. In Caucasian AS patients, the presence of HLA-B27 is related to an earlier disease onset and higher family aggregation. Absence of HLA-B27 is related to a higher frequency of peripheral arthritis, dactylitis, and extra-articular manifestations. Being HLAB27 positive is not related to a higher burden of disease or anytime uveitis.

ACS Style

Marta Arévalo; REGISPONSER group; Jordi Gratacós Masmitjà; Mireia Moreno; Joan Calvet; Cristobal Orellana; Desirée Ruiz; Carmen Castro; Pilar Carreto; Marta Larrosa; Eduardo Collantes; Pilar Font. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Research & Therapy 2018, 20, 1 -6.

AMA Style

Marta Arévalo, REGISPONSER group, Jordi Gratacós Masmitjà, Mireia Moreno, Joan Calvet, Cristobal Orellana, Desirée Ruiz, Carmen Castro, Pilar Carreto, Marta Larrosa, Eduardo Collantes, Pilar Font. Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Research & Therapy. 2018; 20 (1):1-6.

Chicago/Turabian Style

Marta Arévalo; REGISPONSER group; Jordi Gratacós Masmitjà; Mireia Moreno; Joan Calvet; Cristobal Orellana; Desirée Ruiz; Carmen Castro; Pilar Carreto; Marta Larrosa; Eduardo Collantes; Pilar Font. 2018. "Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database." Arthritis Research & Therapy 20, no. 1: 1-6.

Journal article
Published: 29 September 2018 in Reumatología Clínica (English Edition)
Reads 0
Downloads 0

Recent data published on biological therapy in axial spondyloarthritis (axSpA) since the last publication of the recommendations of the Spanish Society of Rheumatology (SER) has led to the generation of a review of these recommendations based on the best possible evidence. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with axSpA. Recommendations were drawn up following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Centre for Evidence Based Medicine at Oxford. The level of agreement was established through the Delphi technique. In this review, we did an update of the evaluation of disease activity and treatment objectives. We included the new drugs with approved therapeutic indication for axSpA. We reviewed both the predictive factors of the therapeutic response and progression of radiographic damage. Finally, we drafted some recommendations for the treatment of patients refractory to anti-tumour necrosis factor, as well as for the possible optimisation of biological therapy. The document also includes a table of recommendations and a treatment algorithm. We present an update of the SER recommendations for the use of biological therapy in patients with axSpA. La aparición de nueva información sobre las terapias biológicas en la espondiloartritis axial (EspAax) ha impulsado una nueva revisión de las recomendaciones de la Sociedad Española de Reumatología (SER) basadas en la mejor evidencia posible. Estas nuevas recomendaciones pueden servir de referencia para reumatólogos implicados en el tratamiento de estos pacientes. Se creó un panel formado por nueve reumatólogos expertos en EspAax, previamente seleccionados por la SER mediante una convocatoria abierta. Las fases del trabajo fueron: identificación de las áreas clave para la actualización del consenso anterior, análisis y síntesis de la evidencia científica (sistema modificado de Oxford, CEBM, 2009) y formulación de recomendaciones a partir de esta evidencia y de técnicas de consenso. Esta revisión de las recomendaciones comporta una actualización en la evaluación de actividad de la enfermedad y objetivos de tratamiento. Incorpora también los nuevos fármacos disponibles, así como sus nuevas indicaciones, y una revisión de los factores predictivos de respuesta terapéutica y progresión del daño radiográfico. Finalmente, estas recomendaciones abordan también las situaciones de fracaso a un primer anti-TNF, así como la posible optimización de la terapia biológica. El documento incluye una tabla de recomendaciones y un algoritmo de tratamiento. Se presenta la actualización de las recomendaciones SER para el uso de terapias biológicas en pacientes con EspAax.

ACS Style

Jordi Gratacós; Petra Díaz Del Campo Fontecha; Cristina Fernández-Carballido; Xavier Juanola Roura; Luis Francisco Linares Ferrando; Eugenio De Miguel Mendieta; Santiago Muñoz Fernández; Jose Luis Rosales-Alexander; Pedro Zarco Montejo; Mercedes Guerra Rodríguez; Victoria Navarro Compán. Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis. Reumatología Clínica (English Edition) 2018, 14, 320 -333.

AMA Style

Jordi Gratacós, Petra Díaz Del Campo Fontecha, Cristina Fernández-Carballido, Xavier Juanola Roura, Luis Francisco Linares Ferrando, Eugenio De Miguel Mendieta, Santiago Muñoz Fernández, Jose Luis Rosales-Alexander, Pedro Zarco Montejo, Mercedes Guerra Rodríguez, Victoria Navarro Compán. Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis. Reumatología Clínica (English Edition). 2018; 14 (6):320-333.

Chicago/Turabian Style

Jordi Gratacós; Petra Díaz Del Campo Fontecha; Cristina Fernández-Carballido; Xavier Juanola Roura; Luis Francisco Linares Ferrando; Eugenio De Miguel Mendieta; Santiago Muñoz Fernández; Jose Luis Rosales-Alexander; Pedro Zarco Montejo; Mercedes Guerra Rodríguez; Victoria Navarro Compán. 2018. "Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis." Reumatología Clínica (English Edition) 14, no. 6: 320-333.

Multicenter study
Published: 01 June 2018 in The Lancet
Reads 0
Downloads 0

Summary Background Guselkumab, a human monoclonal antibody that binds to the p19 subunit of interleukin 23, has been approved for the treatment of moderate-to-severe psoriasis. Psoriatic arthritis is a common comorbidity of psoriasis with an umet need for novel treatments. We assessed the efficacy and safety of guselkumab in patients with active psoriatic arthritis. Methods We did a randomised, double-blind, placebo-controlled, phase 2a trial at 34 rheumatology and dermatology practices in Canada, Germany, Poland, Romania, Russia, Spain, and the USA. Eligible participants were aged 18 years or older with active psoriatic arthritis and plaque psoriasis affecting at least 3% of their body surface area, with three or more of 66 tender joints and three or more of 68 swollen joints, who had an inadequate response or intolerance to standard treatments. We randomly assigned patients (2:1) via a central interactive web-response system using computer-generated permuted blocks with a block size of six, stratified by previous anti-tumour necrosis factor-α use, to receive subcutaneous guselkumab 100 mg or placebo at week 0, week 4, and every 8 weeks thereafter for 24 weeks. Patients, investigators, and site staff were masked to treatment assignment until final database lock at week 56. At week 16, patients with less than 5% improvement in swollen and tender joint counts were eligible for early escape to ustekinumab. At week 24, the remaining placebo-treated patients crossed over to receive guselkumab 100 mg at weeks 24, 28, 36, and 44 and guselkumab-treated patients received a placebo injection at week 24, followed by guselkumab injections at weeks 28, 36, and 44. The primary endpoint was the proportion of patients with at least 20% improvement at week 24 in signs and symptoms of psoriatic arthritis according to American College of Rheumatology criteria (ACR20) in the modified intention-to-treat population (ie, all randomly assigned patients who received at least one dose of study treatment). Safety analyses included patients according to the study drug received. This study is registered with ClinicalTrials.gov, number NCT02319759. Findings Between March 27, 2015, and Jan 17, 2017, we randomly assigned 149 patients to treatment: 100 to guselkumab and 49 to placebo. 17 (35%) of 49 patients in the placebo group and ten (10%) of 100 patients in the guselkumab group were eligible for early escape to ustekinumab at week 16. 29 (59%) of 49 patients in the placebo group crossed over and received guselkumab at week 24. Three (6%) of 49 patients in the placebo group, one (3%) of 29 patients who crossed over from placebo to guselkumab, and six (6%) of 100 patients in the guselkumab group discontinued study treatment before week 44. 58 (58%) of 100 patients in the guselkumab group and nine (18%) of 49 patients in the placebo group achieved an ACR20 response at week 24 (percentage difference 39·7% [95% CI 25·3–54·1]; p<0·0001). Between week 0 and week 24, 36 (36%) of 100 guselkumab-treated patients and 16 (33%) of 49 placebo-treated patients had at least one adverse event. The most frequent adverse event was infection in both groups (16 [16%] of 100 patients in the guselkumab group vs ten [20%] of 49 patients in the placebo group). The prevalence of adverse events between week 0 and week 56 in guselkumab-treated patients (51 [40%] of 129) indicated no disproportional increase with longer guselkumab exposure. No deaths occurred. Interpretation Guselkumab, a novel anti-interleukin 23p19 antibody, significantly improved signs and symptoms of active psoriatic arthritis and was well tolerated during 44 weeks of treatment. The results of this study support further development of guselkumab as a novel and comprehensive treatment in psoriatic arthritis. Funding Janssen Research & Development.

ACS Style

Atul Deodhar; Alice B Gottlieb; Wolf-Henning Boehncke; Bin Dong; Yuhua Wang; Yanli Zhuang; William Barchuk; Xie L Xu; Elizabeth C Hsia; Jacob Aelion; Juan Amarelo-Ramos; Alejandro Balsa; Florian Berghea; Jan Brzezicki; Michael Burnette; Scott Fretzin; Sara García-Carazo; Geoffrey Gladstein; Juan Gomez-Reino; Melinda Gooderham; Carlos González-Fernández; Jordi Gratacos; Derek Haaland; Rima Kamalova; Piotr Leszczynski; Emilio Martin-Mola; Alexey Maslyansky; Federico Navarro; Daniela Opris; Kim Papp; Yuri Perlamutrov; Sandra Philipp; Artur Racewicz; Andrey Rebrov; Maria Rell-Bakalarska; David Rosmarin; Andrea Rubbert-Roth; William Shergy; Ivan Shirinsky; Dmitry Sonin; Marina Stanislav; Alexey Sukharev; Vadim Temnikov; Irina Vinogradova; Paul Waytz; Vladimir Yakushevich. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet 2018, 391, 2213 -2224.

AMA Style

Atul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, Bin Dong, Yuhua Wang, Yanli Zhuang, William Barchuk, Xie L Xu, Elizabeth C Hsia, Jacob Aelion, Juan Amarelo-Ramos, Alejandro Balsa, Florian Berghea, Jan Brzezicki, Michael Burnette, Scott Fretzin, Sara García-Carazo, Geoffrey Gladstein, Juan Gomez-Reino, Melinda Gooderham, Carlos González-Fernández, Jordi Gratacos, Derek Haaland, Rima Kamalova, Piotr Leszczynski, Emilio Martin-Mola, Alexey Maslyansky, Federico Navarro, Daniela Opris, Kim Papp, Yuri Perlamutrov, Sandra Philipp, Artur Racewicz, Andrey Rebrov, Maria Rell-Bakalarska, David Rosmarin, Andrea Rubbert-Roth, William Shergy, Ivan Shirinsky, Dmitry Sonin, Marina Stanislav, Alexey Sukharev, Vadim Temnikov, Irina Vinogradova, Paul Waytz, Vladimir Yakushevich. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet. 2018; 391 (10136):2213-2224.

Chicago/Turabian Style

Atul Deodhar; Alice B Gottlieb; Wolf-Henning Boehncke; Bin Dong; Yuhua Wang; Yanli Zhuang; William Barchuk; Xie L Xu; Elizabeth C Hsia; Jacob Aelion; Juan Amarelo-Ramos; Alejandro Balsa; Florian Berghea; Jan Brzezicki; Michael Burnette; Scott Fretzin; Sara García-Carazo; Geoffrey Gladstein; Juan Gomez-Reino; Melinda Gooderham; Carlos González-Fernández; Jordi Gratacos; Derek Haaland; Rima Kamalova; Piotr Leszczynski; Emilio Martin-Mola; Alexey Maslyansky; Federico Navarro; Daniela Opris; Kim Papp; Yuri Perlamutrov; Sandra Philipp; Artur Racewicz; Andrey Rebrov; Maria Rell-Bakalarska; David Rosmarin; Andrea Rubbert-Roth; William Shergy; Ivan Shirinsky; Dmitry Sonin; Marina Stanislav; Alexey Sukharev; Vadim Temnikov; Irina Vinogradova; Paul Waytz; Vladimir Yakushevich. 2018. "Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study." The Lancet 391, no. 10136: 2213-2224.

Multicenter study
Published: 08 May 2018 in Clinical and experimental rheumatology
Reads 0
Downloads 0
ACS Style

Mireia Moreno; Jordi Gratacós; Victoria Navarro-Compán; Eugenio De Miguel; Pilar Font; Teresa Clavaguera; Luis Francisco Linares; Beatriz Joven; Xavier Juanola; and the Regisponserbio group.. Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides). Clinical and experimental rheumatology 2018, 36, 1038 -1042.

AMA Style

Mireia Moreno, Jordi Gratacós, Victoria Navarro-Compán, Eugenio De Miguel, Pilar Font, Teresa Clavaguera, Luis Francisco Linares, Beatriz Joven, Xavier Juanola, and the Regisponserbio group.. Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides). Clinical and experimental rheumatology. 2018; 36 (6):1038-1042.

Chicago/Turabian Style

Mireia Moreno; Jordi Gratacós; Victoria Navarro-Compán; Eugenio De Miguel; Pilar Font; Teresa Clavaguera; Luis Francisco Linares; Beatriz Joven; Xavier Juanola; and the Regisponserbio group.. 2018. "Should over-treatment of axial spondyloarthritis with biologics remain a concern after the issue of the new ASAS criteria? Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)." Clinical and experimental rheumatology 36, no. 6: 1038-1042.

Journal article
Published: 01 May 2018 in Reumatología Clínica (English Edition)
Reads 0
Downloads 0
ACS Style

Raquel Almodóvar; Juan C. Torre Alonso; Enrique Batlle; Concepción Castillo; Eduardo Collantes-Estevez; Eugenio De Miguel; Senen Gonzalez; Jordi Gratacós; Azucena Hernández; Xavier Juanola; Luis F. Linares; Manuel J. Moreno; Mireia Moreno; Victoria Navarro-Compán; Carlos Rodriguez Lozano; Jesus Sanz; Agusti Sellas; Estíbaliz Loza; Pedro Zarco. Development of a Checklist for Patients With Axial Spondyloarthritis and Psoriatic Arthritis in Daily Practice: ONLY TOOLS Project. Reumatología Clínica (English Edition) 2018, 14, 155 -159.

AMA Style

Raquel Almodóvar, Juan C. Torre Alonso, Enrique Batlle, Concepción Castillo, Eduardo Collantes-Estevez, Eugenio De Miguel, Senen Gonzalez, Jordi Gratacós, Azucena Hernández, Xavier Juanola, Luis F. Linares, Manuel J. Moreno, Mireia Moreno, Victoria Navarro-Compán, Carlos Rodriguez Lozano, Jesus Sanz, Agusti Sellas, Estíbaliz Loza, Pedro Zarco. Development of a Checklist for Patients With Axial Spondyloarthritis and Psoriatic Arthritis in Daily Practice: ONLY TOOLS Project. Reumatología Clínica (English Edition). 2018; 14 (3):155-159.

Chicago/Turabian Style

Raquel Almodóvar; Juan C. Torre Alonso; Enrique Batlle; Concepción Castillo; Eduardo Collantes-Estevez; Eugenio De Miguel; Senen Gonzalez; Jordi Gratacós; Azucena Hernández; Xavier Juanola; Luis F. Linares; Manuel J. Moreno; Mireia Moreno; Victoria Navarro-Compán; Carlos Rodriguez Lozano; Jesus Sanz; Agusti Sellas; Estíbaliz Loza; Pedro Zarco. 2018. "Development of a Checklist for Patients With Axial Spondyloarthritis and Psoriatic Arthritis in Daily Practice: ONLY TOOLS Project." Reumatología Clínica (English Edition) 14, no. 3: 155-159.

Journal article
Published: 01 May 2018 in Reumatología Clínica
Reads 0
Downloads 0
ACS Style

Raquel Almodovar; Juan C. Torre Alonso; Enrique Batlle; Concepción Castillo; Eduardo Collantes-Estevez; Eugenio De Miguel; Senén González; Jordi Gratacós; Azucena Hernández; Xavier Juanola; Luis F. Linares; Manuel J. Moreno; Mireia Moreno; Victoria Navarro-Compán; Carlos Rodríguez Lozano; Jesus Sanz; Agustí Sellas; Estíbaliz Loza; Pedro Zarco. Desarrollo de un cuadro de actuación para la evaluación de pacientes con espondiloartritis axial y artritis psoriásica en la práctica diaria: proyecto ONLY TOOLS. Reumatología Clínica 2018, 14, 155 -159.

AMA Style

Raquel Almodovar, Juan C. Torre Alonso, Enrique Batlle, Concepción Castillo, Eduardo Collantes-Estevez, Eugenio De Miguel, Senén González, Jordi Gratacós, Azucena Hernández, Xavier Juanola, Luis F. Linares, Manuel J. Moreno, Mireia Moreno, Victoria Navarro-Compán, Carlos Rodríguez Lozano, Jesus Sanz, Agustí Sellas, Estíbaliz Loza, Pedro Zarco. Desarrollo de un cuadro de actuación para la evaluación de pacientes con espondiloartritis axial y artritis psoriásica en la práctica diaria: proyecto ONLY TOOLS. Reumatología Clínica. 2018; 14 (3):155-159.

Chicago/Turabian Style

Raquel Almodovar; Juan C. Torre Alonso; Enrique Batlle; Concepción Castillo; Eduardo Collantes-Estevez; Eugenio De Miguel; Senén González; Jordi Gratacós; Azucena Hernández; Xavier Juanola; Luis F. Linares; Manuel J. Moreno; Mireia Moreno; Victoria Navarro-Compán; Carlos Rodríguez Lozano; Jesus Sanz; Agustí Sellas; Estíbaliz Loza; Pedro Zarco. 2018. "Desarrollo de un cuadro de actuación para la evaluación de pacientes con espondiloartritis axial y artritis psoriásica en la práctica diaria: proyecto ONLY TOOLS." Reumatología Clínica 14, no. 3: 155-159.

Public health
Published: 07 February 2018 in Rheumatology International
Reads 0
Downloads 0

To define and give priority to standards of care and quality indicators of multidisciplinary care for patients with psoriatic arthritis (PsA). A systematic literature review on PsA standards of care and quality indicators was performed. An expert panel of rheumatologists and dermatologists who provide multidisciplinary care was established. In a consensus meeting group, the experts discussed and developed the standards of care and quality indicators and graded their priority, agreement and also the feasibility (only for quality indicators) following qualitative methodology and a Delphi process. Afterwards, these results were discussed with 2 focus groups, 1 with patients, another with health managers. A descriptive analysis is presented. We obtained 25 standards of care (9 of structure, 9 of process, 7 of results) and 24 quality indicators (2 of structure, 5 of process, 17 of results). Standards of care include relevant aspects in the multidisciplinary care of PsA patients like an appropriate physical infrastructure and technical equipment, the access to nursing care, labs and imaging techniques, other health professionals and treatments, or the development of care plans. Regarding quality indicators, the definition of multidisciplinary care model objectives and referral criteria, the establishment of responsibilities and coordination among professionals and the active evaluation of patients and data collection were given a high priority. Patients considered all of them as important. This set of standards of care and quality indicators for the multidisciplinary care of patients with PsA should help improve quality of care in these patients.

ACS Style

Jordi Gratacós; Jesús Luelmo; Jesus Rodriguez; Jaume Notario; Teresa Navío Marco; Pablo De La Cueva; Manel Pujol Busquets; Mercè García Font; Beatriz Joven; Raquel Rivera; Jose Luis Alvarez Vega; Antonio Javier Chaves Álvarez; Ricardo Sánchez Parera; Jose Carlos Ruiz Carrascosa; Fernando José Rodríguez Martínez; Jose Pardo Sanchez; Carlos Feced Olmos; Conrad Pujol; Eva Galindez; Santiago Barrio; Ana Urruticoechea Arana; Mercedes Hergueta; Pablo Coto; Rubén Queiró. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. Rheumatology International 2018, 38, 1115 -1124.

AMA Style

Jordi Gratacós, Jesús Luelmo, Jesus Rodriguez, Jaume Notario, Teresa Navío Marco, Pablo De La Cueva, Manel Pujol Busquets, Mercè García Font, Beatriz Joven, Raquel Rivera, Jose Luis Alvarez Vega, Antonio Javier Chaves Álvarez, Ricardo Sánchez Parera, Jose Carlos Ruiz Carrascosa, Fernando José Rodríguez Martínez, Jose Pardo Sanchez, Carlos Feced Olmos, Conrad Pujol, Eva Galindez, Santiago Barrio, Ana Urruticoechea Arana, Mercedes Hergueta, Pablo Coto, Rubén Queiró. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain. Rheumatology International. 2018; 38 (6):1115-1124.

Chicago/Turabian Style

Jordi Gratacós; Jesús Luelmo; Jesus Rodriguez; Jaume Notario; Teresa Navío Marco; Pablo De La Cueva; Manel Pujol Busquets; Mercè García Font; Beatriz Joven; Raquel Rivera; Jose Luis Alvarez Vega; Antonio Javier Chaves Álvarez; Ricardo Sánchez Parera; Jose Carlos Ruiz Carrascosa; Fernando José Rodríguez Martínez; Jose Pardo Sanchez; Carlos Feced Olmos; Conrad Pujol; Eva Galindez; Santiago Barrio; Ana Urruticoechea Arana; Mercedes Hergueta; Pablo Coto; Rubén Queiró. 2018. "Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain." Rheumatology International 38, no. 6: 1115-1124.

Journal article
Published: 01 February 2018 in Osteoarthritis and Cartilage
Reads 0
Downloads 0

Different patterns of association between synovial fluid adipokines were observed regarding pain and disability in knee osteoarthritis patients. Specifically, adiponectin was associated to pain while resistin and visfatin were mainly related to function.

ACS Style

J. Calvet; C. Orellana; N. Albiñana Giménez; A. Berenguer-Llergo; A. Caixàs; M. García-Manrique; C. Galisteo Lencastre; N. Navarro; M. Larrosa; J. Gratacós. Differential involvement of synovial adipokines in pain and physical function in female patients with knee osteoarthritis. A cross-sectional study. Osteoarthritis and Cartilage 2018, 26, 276 -284.

AMA Style

J. Calvet, C. Orellana, N. Albiñana Giménez, A. Berenguer-Llergo, A. Caixàs, M. García-Manrique, C. Galisteo Lencastre, N. Navarro, M. Larrosa, J. Gratacós. Differential involvement of synovial adipokines in pain and physical function in female patients with knee osteoarthritis. A cross-sectional study. Osteoarthritis and Cartilage. 2018; 26 (2):276-284.

Chicago/Turabian Style

J. Calvet; C. Orellana; N. Albiñana Giménez; A. Berenguer-Llergo; A. Caixàs; M. García-Manrique; C. Galisteo Lencastre; N. Navarro; M. Larrosa; J. Gratacós. 2018. "Differential involvement of synovial adipokines in pain and physical function in female patients with knee osteoarthritis. A cross-sectional study." Osteoarthritis and Cartilage 26, no. 2: 276-284.

Journal article
Published: 01 November 2017 in Reumatología Clínica
Reads 0
Downloads 0
ACS Style

Marta Arévalo; Mireia Moreno; Jordi Gratacós. Dermatitis intersticial granulomatosa asociada al lupus: a propósito de un caso. Reumatología Clínica 2017, 13, 367 -368.

AMA Style

Marta Arévalo, Mireia Moreno, Jordi Gratacós. Dermatitis intersticial granulomatosa asociada al lupus: a propósito de un caso. Reumatología Clínica. 2017; 13 (6):367-368.

Chicago/Turabian Style

Marta Arévalo; Mireia Moreno; Jordi Gratacós. 2017. "Dermatitis intersticial granulomatosa asociada al lupus: a propósito de un caso." Reumatología Clínica 13, no. 6: 367-368.